



PolypDx™: Saving Lives Through Early Detection

Colorectal Cancer

- Colorectal cancer is the **second leading** cause of cancer-related deaths in the United States and the third most common cancer.
- The relative 5-year survival rate for colorectal cancer when diagnosed at an early stage is about 90%, however only about 40% colorectal cancers are found at that early stage. Detecting cancer is simply too late. Cancer prevention should be the aim of screening.



Scan this barcode or go to

<http://atlanticdiagnosticlaboratories.com/polypdx.php>

to learn how you can give your patients the PolypDx™ test

Benefits of PolypDx™

- PolypDx™ is the first and only urine based test with a high sensitivity for detecting adenomatous polyps.
- A positive PolypDx™ result suggest that your patient has a high risk of polyps and should receive a colonoscopy
- PolypDx™ was validated in two separate clinical trials of 1000 patients each, demonstrating a higher sensitivity than the fecal based tests (FOBT/FIT) for detecting adenomatous polyps.
- PolypDx™ is fast and simple — just a small urine sample is required! PolypDx™ is intended for individuals at average to moderate risk for colorectal cancer. Screening should be performed annually for those between 50 and 74 years.